Department of Biological Sciences, Virginia Tech, Blacksburg, Virginia, USA.
Virginia Tech Center for Drug Discovery, Virginia Tech, Blacksburg, Virginia, USA.
mSphere. 2021 Mar 3;6(2):e00129-21. doi: 10.1128/mSphere.00129-21.
The bacterial type IV pilus (T4P) is a prominent virulence factor in many significant human pathogens, some of which have become increasingly antibiotic resistant. Antivirulence chemotherapeutics are considered a promising alternative to antibiotics because they target the disease process instead of bacterial viability. However, a roadblock to the discovery of anti-T4P compounds is the lack of a high-throughput screen (HTS) that can be implemented relatively easily and economically. Here, we describe the first HTS for the identification of inhibitors specifically against the T4P assembly ATPase PilB PilB (PilB) had been demonstrated to have robust ATPase activity and the ability to bind its expected ligands We utilized PilB and MANT-ATP, a fluorescent ATP analog, to develop a binding assay and adapted it for an HTS. As a proof of principle, we performed a pilot screen with a small compound library of kinase inhibitors and identified quercetin as a PilB inhibitor Using as a model bacterium, we found quercetin to reduce its T4P-dependent motility and T4P assembly These results validated our HTS as effective in identifying PilB inhibitors. This assay may prove valuable in seeking leads for the development of antivirulence chemotherapeutics against PilB, an essential and universal component of all bacterial T4P systems. Many bacterial pathogens use their type IV pili (T4P) to facilitate and maintain infection of a human host. Small chemical compounds that inhibit the production or assembly of T4P hold promise in the treatment and prevention of infections, especially in the era of increasing threats from antibiotic-resistant bacteria. However, few chemicals are known to have inhibitory or anti-T4P activity. Their identification has not been easy due to the lack of a method for the screening of compound collections or libraries on a large scale. Here, we report the development of an assay that can be scaled up to screen compound libraries for inhibitors of a critical T4P assembly protein. We further demonstrate that it is feasible to use whole cells to examine potential inhibitors for their activity against T4P assembly in a bacterium.
细菌 IV 型菌毛(T4P)是许多重要人类病原体的重要毒力因子,其中一些病原体对抗生素的耐药性越来越强。抗病毒化学疗法被认为是抗生素的一种有前途的替代品,因为它们针对的是疾病过程而不是细菌的生存能力。然而,发现抗 T4P 化合物的一个障碍是缺乏一种可以相对容易和经济地实施的高通量筛选(HTS)。在这里,我们描述了第一个用于鉴定专门针对 T4P 组装 ATP 酶 PilB 的抑制剂的 HTS。已经证明 PilB 具有强大的 ATP 酶活性和结合其预期配体的能力。我们利用 PilB 和荧光 ATP 类似物 MANT-ATP 开发了一种结合测定法,并将其改编为 HTS。作为原理的证明,我们用一个小的激酶抑制剂化合物文库进行了一个初步筛选,并发现槲皮素是 PilB 的抑制剂。使用作为模式细菌,我们发现槲皮素减少了其 T4P 依赖性运动性和 T4P 组装。这些结果验证了我们的 HTS 能够有效地鉴定 PilB 抑制剂。该测定法可能在寻找针对所有细菌 T4P 系统中必不可少且普遍存在的 PilB 的抗病毒化学疗法先导化合物方面具有价值。许多细菌病原体利用其 IV 型菌毛(T4P)来促进和维持对人类宿主的感染。抑制 T4P 产生或组装的小分子化合物在治疗和预防感染方面具有很大的希望,尤其是在抗生素耐药细菌威胁日益增加的时代。然而,已知很少有化学物质具有抑制或抗 T4P 活性。由于缺乏大规模筛选化合物集合或文库的方法,它们的鉴定并不容易。在这里,我们报告了一种测定法的开发,该测定法可以扩展到筛选抑制剂文库,以鉴定关键 T4P 组装蛋白的抑制剂。我们进一步证明,使用整个细胞检查潜在抑制剂对细菌中 T4P 组装的活性是可行的。